Tags · Compound
tirzepatide
Dual GIP and GLP-1 receptor agonist.
Related in this group: semaglutide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues
73 topics · page 1 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
|
+52 | 57 | 25k | just now |
|
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…
|
+2 | 6 | 5.5k | 7h |
|
Restarting after a long gap: what the labelling implies
Posting this under the heading it deserves: Restarting after a long gap: what the labelling implies Everything below is what sits behind that. I have read the maintained page on this and I still have a gap,…
|
+41 | 46 | 11k | 15h |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be
What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…
|
+16 | 20 | 23k | 19h |
|
When a dose reduction is the correct response to a side effect
When a dose reduction is the correct response to a side effect — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I…
|
+38 | 42 | 2.7k | 19h |
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…
|
+90 | 98 | 30k | 22h |
|
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. Reporting something rather than asking about it, in case the…
|
+31 | 35 | 2k | 1d |
|
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. I have read the maintained page on this and I…
|
+44 | 48 | 11k | 1d |
|
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means…
|
+57 | 61 | 708 | 1d |
|
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. A question about technique rather than about dose. I have been doing the…
|
+99 | 110 | 61k | 2d |
|
Stepping down deliberately, and how to do it without losing progress — what changed since
Posting this under the heading it deserves: Stepping down deliberately, and how to do it without losing progress — what changed since Everything below is what sits behind that. Practical question with the…
|
+94 | 99 | 29k | 2d |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…
|
+17 | 21 | 17k | 12d |
|
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
+6 | 10 | 34k | 20d |
|
Does dual agonism explain the effect size, or is it dose?
Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…
|
+62 | 68 | 2.6k | 29d |
|
When a dose reduction is the correct response to a side effect — a second dataset
When a dose reduction is the correct response to a side effect — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on…
|
+10 | 14 | 42k | 2mo |
|
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. I would like to understand what this number means before I repeat it anywhere. A…
|
+58 | 64 | 9.7k | 2mo |
|
Restarting after a long gap: what the labelling implies — the long version
Restarting after a long gap: what the labelling implies — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+12 | 17 | 2.4k | 2mo |
|
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…
|
+109 | 122 | 3.6k | 2mo |
|
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+11 | 15 | 43k | 2mo |
|
Revisiting: The arithmetic of an intermediate dose between two label steps
Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+41 | 45 | 808 | 2mo |
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in…
|
+73 | 78 | 3.5k | 2mo |
|
Stepping down deliberately, and how to do it without losing progress
Stepping down deliberately, and how to do it without losing progress — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
|
+98 | 102 | 26k | 3mo |
|
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. semaglutide…
|
+14 | 18 | 15k | 3mo |
|
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
|
+24 | 28 | 51k | 5mo |
|
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
|
+124 | 133 | 11k | 5mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?
Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…
|
+7 | 11 | 281 | 6mo |
|
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset
Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…
|
+12 | 16 | 11k | 7mo |
|
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+5 | 9 | 21k | 7mo |
|
Reading SURMOUNT-1 without the press release
Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a claim I do not…
|
+103 | 121 | 7k | 7mo |
|
Why tirzepatide titration schedules have more steps than semaglutide's
Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
4 | 8.4k | 7mo |